Roger Bakale Email & Phone Number | Dr. Bakale has thirty-eight years of Pharmaceutical R&D experience and is currently Senior Vice President, CMC head, Clinical and Commercial Manufacturing at Kura Oncology. Previously, he was Vice President of CMC-Product Development & Manufacturing Bristol-Myers Squibb (formerly Celgene). Before the Bristol-Myers Squibb and Celgene merger, he was Vice President CMC & Clinical Supply Chain at Receptos Inc. Prior to joining Receptos, he was the Sr. Director and Head of Chemical Process R&D in the Discovery & Product Development division of Teva Global R&D after the Cephalon/Teva merger. Prior to joining Cephalon/Teva, he held Senior Managerial and Research and Development positions at Sepracor Inc. (Sunovion), and scientific leadership positions at Bristol-Myers Squibb, and Warner Lambert Parke Davis. He is responsible for directing the scientific teams engaged in chemical innovation and product development, as well as providing strategic leadership in drug development activities from candidate nomination through clinical development and commercial regulatory approval. Dr. Bakale has participated in the identification of New Therapeutic Entity (NTE) and Improved Chemical Entity (ICE) strategies for drug development, life cycle management initiatives and business development diligence evaluations of new drug candidates. He has been responsible for leading the CMC organizations associated with the successful technology transfers of commercial API and drug product launches for seven new patient therapies including: Zeposia, Treanda, Synribo, Xopenex HCl, Xopenex HFA, Lunesta, Bravana, Soltara and also significantly contributing to the technical approval packages of Paclitaxel, and Fosinopril Sodium. Dr. Bakale received his BSc in Chemistry and BSc in Biology at Hope College and his Ph.D. in Synthetic Organic Chemistry under the direction of Professor Carl R. Johnson at Wayne State University. He has co-authored ninety-two patents and publications and presented over ninety-five abstracts and scientific presentations. He is a member and active participant in numerous professional societies and two advisory boards and served on the scientific editorial board of the America Chemical Society Journal - Organic Process Research and Development, and the Scientific Board of Directors for the Chemical and Pharmaceutical Ingredients conferences (CPhI Worldwide and North America).

Roger Bakale

Dr. Bakale has thirty-eight years of Pharmaceutical R&D experience and is currently Senior Vice Pres...
San Diego, San Diego, United States

*50 free lookup(s) per month.

No credit card required.

Roger Bakale’s Email roger@kuraoncology.com

Roger Bakale’s Phone Numbers

Get ROGER’s Phone Number (For Free)

Social Media

Roger Bakale’s Location San Diego, San Diego, United States

Roger Bakale’s Current Industry Kura Oncology

Not the Roger Bakale you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Kura Oncology

Senior Vice President, Head CMC, Clinical and Commercial Manufacturing

2023-06-01 00:00:00 - Present

Celgene

VP, CMC - Product Development and Mfg.

2014-12-01 00:00:00 - 2020-04-01 00:00:00

Teva Pharmaceuticals

Sr. Director, Chemical Process R&D

2011-11-01 00:00:00 - 2014-12-01 00:00:00

Cephalon

Sr. Director WW Chemical Process R&D

2007-07-01 00:00:00 - 2011-10-01 00:00:00

Sepracor

Executive Director CPRD

1993-01-01 00:00:00 - 2007-01-01 00:00:00

Bristol Myers Squibb

Sr. Research Investgator II

1988-01-01 00:00:00 - 1993-01-01 00:00:00

Warner Lambert Parke Davis

Research Associate

1981-05-01 00:00:00 - 1983-08-01 00:00:00

Skills

No Skills Available

Languages

No Languages Available

FAQ About Roger Bakale

Roger Bakale is located at
San Diego, San Diego, United States

Roger Bakale is a Dr. Bakale has thirty-eight years of Pharmaceutical R&D experience and is currently Senior Vice President, CMC head, Clinical and Commercial Manufacturing at Kura Oncology. Previously, he was Vice President of CMC-Product Development & Manufacturing Bristol-Myers Squibb (formerly Celgene). Before the Bristol-Myers Squibb and Celgene merger, he was Vice President CMC & Clinical Supply Chain at Receptos Inc. Prior to joining Receptos, he was the Sr. Director and Head of Chemical Process R&D in the Discovery & Product Development division of Teva Global R&D after the Cephalon/Teva merger. Prior to joining Cephalon/Teva, he held Senior Managerial and Research and Development positions at Sepracor Inc. (Sunovion), and scientific leadership positions at Bristol-Myers Squibb, and Warner Lambert Parke Davis. He is responsible for directing the scientific teams engaged in chemical innovation and product development, as well as providing strategic leadership in drug development activities from candidate nomination through clinical development and commercial regulatory approval. Dr. Bakale has participated in the identification of New Therapeutic Entity (NTE) and Improved Chemical Entity (ICE) strategies for drug development, life cycle management initiatives and business development diligence evaluations of new drug candidates. He has been responsible for leading the CMC organizations associated with the successful technology transfers of commercial API and drug product launches for seven new patient therapies including: Zeposia, Treanda, Synribo, Xopenex HCl, Xopenex HFA, Lunesta, Bravana, Soltara and also significantly contributing to the technical approval packages of Paclitaxel, and Fosinopril Sodium. Dr. Bakale received his BSc in Chemistry and BSc in Biology at Hope College and his Ph.D. in Synthetic Organic Chemistry under the direction of Professor Carl R. Johnson at Wayne State University. He has co-authored ninety-two patents and publications and presented over ninety-five abstracts and scientific presentations. He is a member and active participant in numerous professional societies and two advisory boards and served on the scientific editorial board of the America Chemical Society Journal - Organic Process Research and Development, and the Scientific Board of Directors for the Chemical and Pharmaceutical Ingredients conferences (CPhI Worldwide and North America).

Roger Bakale currently works in the Kura Oncology |

No Languages Available

Roger Bakale has prior
experience in the following industries:
Celgene | Teva Pharmaceuticals | Cephalon | Sepracor | Bristol Myers Squibb | Warner Lambert Parke Davis

Roger Bakale has the following professional experience:
Kura Oncology | Celgene | Teva Pharmaceuticals | Cephalon | Sepracor | Bristol Myers Squibb | Warner Lambert Parke Davis